36 results on '"Bachas, Costa"'
Search Results
2. Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML
3. Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometry
4. P432: VALIDATION OF LIMIT OF QUANTIFICATION APPROACH BASED FLOW CYTOMETRY FOR MEASURABLE RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA IN THE HOVON-SAKK-132 TRIAL
5. P475: EMERGING LEUKEMIA ASSOCIATED IMMUNOPHENOTYPES (LAIPS) IN BONE MARROW OF ACUTE MYELOID LEUKEMIA PATIENTS AFTER INTENSIVE CHEMOTHERAPY.
6. P448: PROGNOSTIC SIGNIFICANCE OF MEASURABLE RESIDUAL DISEASE DETECTION BY FLOW CYTOMETRY IN AUTOLOGOUS STEM CELL APHERESIS PRODUCTS OF PATIENTS WITH AML
7. Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival
8. Prospective Validation of the Prognostic Relevance of CD34+CD38- AML Stem Cell frequency in the HOVON-SAKK132 trial
9. Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements
10. Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching
11. Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis
12. Characterization of myelodysplastic syndromes hematopoietic stem and progenitor cells using mass cytometry
13. Characteristics of leukemic stem cells in acute leukemia and potential targeted therapies for their specific eradication
14. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
15. Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party
16. Computational flow cytometry as a diagnostic tool in suspected‐myelodysplastic syndromes
17. Machine Learning-Based Flow Cytometry Diagnostics in Myelodysplastic Syndromes: Validation in the HOVON89 Clinical Trial (EudraCT 2008-002195-10)
18. Harnessing Gene Expression Profiles for the Identification of Ex Vivo Drug Response Genes in Pediatric Acute Myeloid Leukemia
19. Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi‐centre setting
20. Computational analysis of flow cytometry data in hematological malignancies: future clinical practice?
21. Re: Myeloblasts in normal bone marrows expressing leukaemia-associated immunophenotypes
22. TP53 mutations and relevance of expression of TP53 pathway genes in paediatric acute myeloid leukaemia
23. Targeting the cell cycle in head and neck cancer by Chk1 inhibition: a novel concept of bimodal cell death
24. Rscreenorm: normalization of CRISPR and siRNA screen data for more reproducible hit selection
25. Gene Expression Profiles Associated with Pediatric Relapsed AML
26. Clinical relevance of molecular aberrations in paediatric acute myeloid leukaemia at first relapse
27. Procedures for the expansion of CD14+precursors from acute myeloid leukemic cells to facilitate dendritic cell-based immunotherapy
28. Harnessing Gene Expression Profiles for the Identification of Drug Resistance Genes in Pediatric AML
29. Frequency and Prognostic Relevance of Gene Mutations in Pediatric AML Patients At First Relapse.
30. Abstract 3209: Gene expression micro array analysis of diagnosis and matched relapse pediatric AML samples indicates that immune regulatory pathways and epigenetic factors are involved in disease progression
31. Relapsed AML Patients with Mutational Shifts Harbor An Oligoclonal Primitive Cell Compartment at Presentation; Evidence for Clonal Selection towards Relapse
32. High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine
33. Abstract A3: Low-frequency subclones in acute myeloid leukemia samples at diagnosis indicate oligoclonality and may play a role in disease progression
34. Frequent Instability of Type I and II Aberrations Between Diagnosis and Relapse Observed in Pediatric Aml; Implications for Targeted Therapy and MRD Detection.
35. Changes in Type I Mutations Between Initial and Relapse Samples of Pediatric AML Patients Occur Frequently and Are Associated with Time to Relapse
36. Identification of a Small Subpopulation of Candidate Leukemia-Initiating Cells in the Side Population of Patients with Acute Myeloid Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.